SpeedWeed

JULY 6, 2021

Safety data is limited, and testing for CRC contamination is missing—even in legalization states. Marcus Moates, the owner of Nature’s Lab Extracts , has been making extracts in the legal market since 2008. The research and safety data on CRC tech products certainly remains thin. What is CRC tech? Wikicommons).

Hash 52

Hash Media Extraction Terpenes 52

SpeedWeed

MARCH 7, 2021

Mark does have quite a bit to share with us, but as always, we’re going to check in with Ed to see what he’s uncovered this week from the data vault. This one was on the advisory sector, which focuses on consultants as well as essentially data analytics firms, so that was fun to dig back into that. View original article.

Extraction 52

Extraction Data Hemp Research and Development 52

Cannabis Law Report

MAY 26, 2022

was published in the Journal of Safety Research and made available online on May 18. Journal of Safety Research. Even absent strict enforcement, an abundance of research has shown the MLDA-21 policy to be very effective in reducing underage impaired driving (Dang, 2008, Decker et al., Available online 18 May 2022.

Dispensary 52

Dispensary Research and Development Safety Recreational 52

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. At the same time, the outlook on cannabis research data is largely positive. 2018 ; Frankhauser 2008 ).

Research and Development 52

Research and Development Medicine Access Media 52

The Cannigma

JANUARY 13, 2023

The authors noted that while “promising data are emerging on the possible role of ECS in migraine…proper placebo-controlled trials are needed to establish a therapeutic role for cannabinoids.” 1 A 2008 study found serotonin and endocannabinoid levels, including anandamide, were lower in people with chronic migraines.

Terpenes 132

Terpenes Strains THC Treatment 132

Cannabis Law Report

APRIL 8, 2022

The FDA formally decided to open the door to psychedelic research in human participants, and later accepted MAPS’ Phase 1 MDMA safety and tolerance study protocol. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer. Rick Doblin, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

OCTOBER 29, 2019

ElleVet Sciences is pleased to announce the results and publication of the first safety study on the use of hemp CBD/CBDA. The 12-week safety study, conducted by Dr. Joseph Wakshlag, DVM, Ph.D., This data gives us confidence in the use of both the chew and the oils as effective means for delivering CBD to your pet.”.

Safety 45

Safety CBD Clinical Trials Oil 45

SpeedWeed

JULY 30, 2021

Data going back to 2005 is included in the commissioned report on the impacts of legalization, which was mandated by the Colorado General Assembly in 2013. . Furthermore, the measurement of available data elements can be affected by [the] very context of marijuana legalization. Traffic Safety. 10, 2012, when Gov.

Business 52

Business Data Safety Cannabinoids 52

SpeedWeed

JULY 30, 2021

Data going back to 2005 is included in the commissioned report on the impacts of legalization, which was mandated by the Colorado General Assembly in 2013. . Furthermore, the measurement of available data elements can be affected by [the] very context of marijuana legalization. Traffic Safety. 10, 2012, when Gov.

Retail 52

Retail Data Safety Cannabinoids 52

SpeedWeed

JULY 31, 2021

Data going back to 2005 is included in the commissioned report on the impacts of legalization, which was mandated by the Colorado General Assembly in 2013. . Furthermore, the measurement of available data elements can be affected by [the] very context of marijuana legalization. Traffic Safety. 10, 2012, when Gov.

Legalization 52

Legalization Data Safety Cannabinoids 52

SpeedWeed

JULY 30, 2021

Data going back to 2005 is included in the commissioned report on the impacts of legalization, which was mandated by the Colorado General Assembly in 2013. . Furthermore, the measurement of available data elements can be affected by [the] very context of marijuana legalization. Traffic Safety. 10, 2012, when Gov.

Data 52

Data Safety Cannabinoids Cannabis 52

SpeedWeed

JULY 30, 2021

Data going back to 2005 is included in the commissioned report on the impacts of legalization, which was mandated by the Colorado General Assembly in 2013. . Furthermore, the measurement of available data elements can be affected by [the] very context of marijuana legalization. Traffic Safety. 10, 2012, when Gov.

Dispensary 52

Dispensary Data Safety Cannabinoids 52

The Cannigma

DECEMBER 8, 2021

We’re often that lone voice over on the corner, looking out for consumers, looking out for their rights and for their safety. It’s not with volumes of data, and facts and figures. JMP: It started in 2008. EG: And then for recreational and medical consumers alike, right? What are they emotionally comfortable with?

Access 81

Access Policy Patients Cannabis 81

Cannabis Law Report

MARCH 25, 2019

15, 2008 , 122 Stat. 5) All books, records, and research, including formulas, microfilm, tapes, and data which are used, or intended for use, in violation of this subchapter. . (6) 2003, 2004, 2007, 2008, Nov. 4002(b)(1)(B), (D), (2)(M), 4115(c)(1)(A)(i), (B)(ii), May 22, 2008 , 122 Stat. 8, 2008 , 122 Stat.

Banking 45

Banking Law Marijuana State Laws 45

Cannabis Law Report

JANUARY 21, 2019

All electronic storage systems must provide a complete and accurate record of your data that is accessible to the IRS. . Taxable Year 2008 – California Conformity to Federal Law. Economic Stimulus Act of 2008 (PL 110-185, H.R. 5140) enacted February 13, 2008. 6081) enacted June 17, 2008.

Seed-To-Sale 40

Seed-To-Sale Business Compliance Compliance 40

Cannabis Law Report

JUNE 4, 2021

Through its discovery platform, Delix has identified a class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Graham contributes to Psilocybin Alpha as editor-at-large, providing data for patent trackers and writing about IP in the psychedelics space. Ingmar Gorman. James Keim.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

NORML

AUGUST 26, 2019

We had lawmakers who were just proposing lists of diseases that they felt were deserving, and we tried very narrow approaches, proposing two diseases, cancer and Crohn’s disease specifically, and we were being met with questions like, “Where are the data on that?”

Marijuana 213

Marijuana Legalization Programs Oil 213